Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 437

1.

Loss of reactivity of vaccine-induced CD4 T cells in immunized monkeys after SIV/HIV challenge.

Puaux AL, Delache B, Marconi S, Huerre M, Le Grand R, Rivière Y, Michel ML.

AIDS. 2005 May 20;19(8):757-65.

PMID:
15867489
2.

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.

Kumar A, Mukherjee S, Shen J, Buch S, Li Z, Adany I, Liu Z, Zhuge W, Piatak M Jr, Lifson J, McClure H, Narayan O.

Virology. 2002 Sep 30;301(2):189-205.

3.

Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.

Bertley FM, Kozlowski PA, Wang SW, Chappelle J, Patel J, Sonuyi O, Mazzara G, Montefiori D, Carville A, Mansfield KG, Aldovini A.

J Immunol. 2004 Mar 15;172(6):3745-57.

4.

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.

Ramsburg E, Rose NF, Marx PA, Mefford M, Nixon DF, Moretto WJ, Montefiori D, Earl P, Moss B, Rose JK.

J Virol. 2004 Apr;78(8):3930-40.

5.

Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles.

Puaux AL, Marsac D, Prost S, Singh MK, Earl P, Moss B, Le Grand R, Riviere Y, Michel ML.

Vaccine. 2004 Sep 9;22(27-28):3535-45.

PMID:
15315833
7.

Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.

Nehete PN, Chitta S, Hossain MM, Hill L, Bernacky BJ, Baze W, Arlinghaus RB, Sastry KJ.

Vaccine. 2001 Dec 12;20(5-6):813-25.

PMID:
11738745
8.

Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.

Kent SJ, Dale CJ, Ranasinghe C, Stratov I, De Rose R, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Wilson KM, Ramsay AJ.

Vaccine. 2005 Oct 10;23(42):5009-21.

PMID:
15985317
9.

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.

Amara RR, Smith JM, Staprans SI, Montefiori DC, Villinger F, Altman JD, O'Neil SP, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McNicholl JM, McClure HM, Moss B, Robinson HL.

J Virol. 2002 Jun;76(12):6138-46.

10.

Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.

Enose Y, Kita M, Yamamoto T, Suzuki H, Miyake A, Horiuchi R, Ibuki K, Kaneyasu K, Kuwata T, Takahashi E, Sakai K, Shinohara K, Miura T, Hayami M.

Arch Virol. 2004 Sep;149(9):1705-20.

PMID:
15593414
11.
12.

Differences between T cell epitopes recognized after immunization and after infection.

Vogel TU, Horton H, Fuller DH, Carter DK, Vielhuber K, O'Connor DH, Shipley T, Fuller J, Sutter G, Erfle V, Wilson N, Picker LJ, Watkins DI.

J Immunol. 2002 Oct 15;169(8):4511-21.

13.
14.

Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens.

Koopman G, Mortier D, Hofman S, Niphuis H, Fagrouch Z, Norley S, Sutter G, Liljeström P, Heeney JL.

J Gen Virol. 2004 Oct;85(Pt 10):2915-24.

PMID:
15448353
16.

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, Fu TM, Finnefrock AC, Handt L, Citron MP, Heidecker G, Tang A, Chen M, Wilson KA, Gabryelski L, McElhaugh M, Carella A, Moyer C, Huang L, Vitelli S, Patel D, Lin J, Emini EA, Shiver JW.

J Virol. 2005 Oct;79(19):12321-31.

17.

Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.

Hel Z, Tsai WP, Thornton A, Nacsa J, Giuliani L, Tryniszewska E, Poudyal M, Venzon D, Wang X, Altman J, Watkins DI, Lu W, von Gegerfelt A, Felber BK, Tartaglia J, Pavlakis GN, Franchini G.

J Immunol. 2001 Dec 15;167(12):7180-91.

18.

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, Miller J, McClure HM, McNicholl JM, Moss B, Robinson HL.

Science. 2001 Apr 6;292(5514):69-74.

19.

Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.

Nacsa J, Radaelli A, Edghill-Smith Y, Venzon D, Tsai WP, Morghen Cde G, Panicali D, Tartaglia J, Franchini G.

Vaccine. 2004 Jan 26;22(5-6):597-606.

PMID:
14741150
20.

Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy.

Shimada M, Wang HB, Kondo A, Xu XP, Yoshida A, Shinoda K, Ura T, Mizuguchi H, Klinman D, Luo JL, Bai H, Okuda K.

Gene Ther. 2009 Feb;16(2):218-28. doi: 10.1038/gt.2008.152. Epub 2008 Oct 16.

PMID:
18923453
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk